Johnson & Johnson's Q1 earnings call revealed a mixed picture, with the company reporting modest operational growth of 1% despite facing headwinds from generic competition and remediation costs in its Consumer segment. The Pharmaceutical segment showed resilience, driven by strong performances from immunology products and new launches. Management guidance for 2012 remains unchanged, with expected operational sales growth of 4-5% and EPS of $5.18-5.28. While the company faces challenges, its diversified portfolio, robust pipeline, and commitment to innovation position it well for long-term growth. The stock is likely to experience short-term volatility due to ongoing macroeconomic uncertainty and industry trends, but its fundamental strengths should support a positive outlook.

[1]